Jonathan Chang

Q: What is Jonathan Chang's success rate?

Jonathan Chang currently has a success rate of 84.88372093023256.

Q: What is the average return of Jonathan Chang's calls?

Their stock ratings have generated an average return of 17.616137925744322.

Leerink Partners | Healthcare

Jonathan Chang is an analyst from Leerink Partners specializing in the Healthcare sector. Ranked #1108 out of 4752 analysts, they have issued 6 stock ratings with a success rate of 84.88% and an average return of 17.62%.

With 6 ratings to date, Jonathan Chang is beginning to establish credibility in the Healthcare sector. They have achieved a success rate of 84.88% and an average return of 17.62%, highlighting promising potential as their track record develops further.

#1108

Out of 4752

Total Ratings

+84.88%

Success Rate

+17.62%

Average Return

Recent Ratings Analysis

REPL

Buy

Aug 04, 2026

Target

$17.00

Current

$11.92

Performance

0.00%

Jonathan Chang rated REPL as Outperform on Aug 04, 2026, setting a price target of 17. Shares have remained stable near 11.92, leaving the 17 target still in play.

WHWK

Buy

Jul 13, 2026

Target

$9.00

Current

$4.14

Performance

7.81%

On Jul 13, 2026, WHWK was given a Outperform rating by Jonathan Chang, with a target price of 9. The stock rallied 7.81% after the rating, narrowing the gap to the target of 9 and validating the bullish stance.

NBTX

Buy

Jun 04, 2026

Target

$46.00

Current

$39.52

Performance

7.07%

NBTX received a Outperform rating from Jonathan Chang on Jun 04, 2026, aiming for 46. Momentum has favored the Buy call, with shares climbing from 39.52 to 39.52, rewarding those who trusted the recommendation.

RVMD

Buy

Apr 22, 2026

Target

$171.00

Current

$193.46

Performance

36.72%

On Apr 22, 2026, Jonathan Chang published a Outperform outlook on RVMD, with a target of 171. Shares gained 36.72%, underscoring the accuracy of the bullish outlook toward 171.

ZLAB

Buy

Jun 30, 2025

Target

$75.00

Current

$18.49

Performance

-47.13%

Jonathan Chang on Jun 30, 2025 assigned ZLAB a Outperform rating, with a price target of 75. The call has struggled to gain traction, with shares losing 47.13%.

GMAB

Buy

Feb 13, 2025

Target

$27.00

Current

$29.02

Performance

38.72%

On Feb 13, 2025, Jonathan Chang reaffirmed GMAB with a Outperform rating, targeting 27. The recommendation was supported by strong follow-through as the stock rose from 29.02 to 29.02.

VINC

Buy

Oct 08, 2024

Target

$2.00

Current

$0.01

Performance

-99.84%

VINC was rated Outperform by Jonathan Chang on Oct 08, 2024, with a price objective of 2. This case shows how bullish projections can fail, with the stock now below 0.0127.

IMCR

Buy

Apr 29, 2024

Target

$74.00

Current

$33.24

Performance

-42.79%

On Apr 29, 2024, Jonathan Chang initiated coverage on IMCR with a Outperform rating and target of 74. The Buy call has yet to be validated as shares remain 40.76 away from the target.

Frequency Asked Questions

Who is Jonathan Chang?

Jonathan Chang is an analyst from Leerink Partners specializing in the Healthcare sector.

What is Jonathan Chang's success rate?

Jonathan Chang currently has a success rate of +84.88%.

How many ratings has Jonathan Chang issued?

Jonathan Chang has issued 6 stock ratings so far.

What is the average return of Jonathan Chang's calls?

Their stock ratings have generated an average return of +17.62%.

What is Jonathan Chang's ranking?

Jonathan Chang is ranked #1108 out of 4752 analysts.

What types of ratings does Jonathan Chang give?

Their ratings include Buy, Hold, and Sell recommendations, depending on the stock’s outlook.

How can I follow Jonathan Chang?

You can follow Jonathan Chang by clicking the "Follow Analyst" button on this page to receive updates on their stock calls.

What is the most recent rating by Jonathan Chang?

Their latest rating was a Buy on REPL issued on 2026-08-04.